Stay updated on Selonsertib for NASH F3 Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Selonsertib for NASH F3 Fibrosis Clinical Trial page.

Latest updates to the Selonsertib for NASH F3 Fibrosis Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now presents a full HTML error document indicating the content is temporarily unavailable, replacing the usual study record information on the page. This reflects a site-side issue rather than a content update.SummaryDifference15%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, indicating a minor release of the site’s page framework. This behind-the-scenes update does not change the visible study details or user-facing content.SummaryDifference0.0%

- Check34 days agoChange DetectedThe term used to describe the liver condition on the page has been updated from Fatty Liver Disease to Steatotic Liver Disease. This reflects a glossary terminology update to align with current clinical language.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing Revision: v3.6.2.SummaryDifference0.0%

- Check55 days agoChange DetectedThe page revision indicator changed from v3.6.0 to v3.6.2, indicating a newer version of the page.SummaryDifference0.0%

- Check69 days agoChange DetectedThe page now displays a 'No longer looking for participants' notice, signaling that recruitment has closed, and adds new help/navigation items such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', along with a new 'Intervention/Treatment' section. The previous 'Intervention / Treatment' heading was removed and the study record revision tag updated from v3.5.5 to v3.6.0, indicating an updated formatting/version change.SummaryDifference0.1%

Stay in the know with updates to Selonsertib for NASH F3 Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selonsertib for NASH F3 Fibrosis Clinical Trial page.